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Adenosine and extracellular volume in radiocontrast media-
induced nephropathy. Renal hemodynamic changes could play a
key role in radiocontrast media-induced nephropathy (RCIN),
although the pathophysiological mechanisms are unclear. We
investigated the role of adenosine in RCIN caused by sodium
diatrizoate (Urografin, 3 ml/kg) in nitro-L-Arg methyl ester
(L-NAME)-hypertensive rats in different hydration states [eight
weeks of L-NAME (50 mg/liter) in drinking water; high or low
sodium intake for the last two weeks]. In clearance experiments
under thiobutabarbital anesthesia in these previously mentioned
animals, glomerular filtration rate (GFR), renal blood flow
(RBF), and mean arterial pressure (MAP) were measured in the
presence or absence of the adenosine A1-receptor antagonist
8-cyclopropyl-1,3-dipropylxanthine (DPCPX, 100 mg/kg bolus
plus 10 mg/kg/hr). DPCPX or pretreatment did not change control
hemodynamics. Contrast medium caused GFR and RBF to fall
significantly in volume-depleted rats (from 0.29 6 0.02 to 0.21 6
0.02 ml/min/100 g and 5.4 6 0.3 to 4.0 6 0.4 ml/min, respectively)
without change in MAP. In volume-expanded rats, changes were
not significant (0.25 6 0.01 to 0.24 6 0.02 ml/min/100 g and 5.6 6
0.3 to 5.3 6 0.4 ml/min, respectively). In the volume-depleted rats,
changes were prevented by DPCPX (0.27 6 0.02 to 0.24 6 0.02
ml/min/100 g and 4.8 6 0.1 to 5.0 6 0.1 ml/min, respectively). The
acute hemodynamic effects elicited by contrast medium in L-
NAME hypertensive rats thus can be prevented by volume
expansion. Adenosine, via A1-receptors, contributes to the ad-
verse effects of contrast media.
Acute renal failure following radiocontrast medium
(RCM) administration is a major adverse event in patients
with impaired renal function and limits the diagnostic use
of RCM in these patients. Hydration is one of the most
effective means of preventing RCM-induced nephropathy
(RCIN) [1]. In patients with congestive heart failure,
however, a volume load may be limited or contraindicated.
Experimental and small clinical trials in patients with
normal renal function have shown that the unspecific
adenosine receptor antagonist theophylline also mitigates
the RCM-induced decline in renal function [2, 3]. Interest-
ingly, in a recent large study in patients with pre-existing
renal dysfunction, glomerular filtration rate (GFR) was
preserved by prehydration alone; theophylline could not
elicit any additional benefit [4].
The nucleoside adenosine is a vasoactive metabolite of
adenosine triphosphate (ATP) hydrolysis: elevated tissue
levels occur in ischemia and increased oxygen consumption.
In contrast to other vascular beds, adenosine vasoconstricts
the kidney, and it is implicated in regulation of tubuloglo-
merular feedback [5]. These actions are mediated primarily
via adenosine A1 receptors. The new animal model of the
nitro-L-Arg methyl ester (L-NAME)-hypertensive, chronic
nitric oxide (NO)-depleted rat with elevated renal vascular
resistance is suitable for studying the pathophysiology of
RCM-induced acute renal failure [6]. To clarify further the
role of adenosine and extracellular volume (ECV) status,
we investigated the renal hemodynamic response to the
RCM sodium diatrizoate in L-NAME-hypertensive rats
with different levels of hydration with and without specific
adenosine A1 receptor antagonism.
METHODS
Hypertension was induced in male Wistar rats by oral
administration of L-NAME (50 mg/l) in the drinking water
for eight weeks. Age-matched, untreated rats served as
controls. Subgroups were either volume expanded (VE,
deoxycorticosterone acetate 1 mg/kg i.p., 1% NaCl in the
drinking water) or volume depleted (VD; furosemide, 20
mg/kg i.p. and low salt diet) during the last 10 days of
pretreatment. Systolic blood pressure (BP) was determined
in conscious animals by tail-cuff measurement. The proto-
col was approved by the Institutional Board for Animal
Use. In clearance experiments, mean arterial pressure
(MAP), GFR, renal blood flow (RBF), urine volume, and
electrolyte excretion were assessed in thiobutabarbital-
anesthetized rats before and after an i.v. bolus of sodium
diatrizoate (76%, Urografin, 3 ml/kg body weight). In VD
rats, 5.5% glucose in 2.5% mannitol was infused instead of
saline to maintain sodium depletion and extracellular de-
hydration. Additional subgroups were treated concomi-
tantly with the specific adenosine A1 receptor-antagonist
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8-cyclopentyl-1 to 3-dipropylxanthine (DPCPX; 100 mg/kg
bolus and 10 mg/kg/h). Control animals received solvent
only. GFR was calculated as the clearance of 3H-inulin;
RBF was measured using an electromagnetic flowmeter.
Urine volume was determined gravimetrically; plasma and
urinary electrolyte concentrations were determined by
flame photometry. Data were analyzed by analysis of
variance; differences in means among groups were com-
pared by Student’s t-test for paired or unpaired compari-
sons as appropriate. Results are given as means 6 SEM.
RESULTS AND DISCUSSION
Systolic BP and protein excretion were elevated signifi-
cantly over controls in conscious L-NAME rats (148 6 13
mm Hg vs. 102 6 10 mm Hg, P , 0.05, and 218 6 8 vs.
166 6 6 mg/day, P , 0.05). MAP remained elevated in
anesthetized L-NAME rats and was lower in VD rats. VD
rats had significantly higher hematocrits than VE (53 6
0.8% vs. 48 6 0.8%, P , 0.05), independent of other
pretreatment. Baseline levels of MAP, GFR, and RBF
were not altered significantly by pretreatment nor by
DPCPX (Table 1). RCM had no significant effect on renal
hemodynamics in normotensive VD or VE rats (Table 1).
In L-NAME-hypertensives, GFR and RBF decreased sig-
nificantly without changes in MAP only in VD (VD/L-
NAME). In VE, GFR and RBF remained constant despite
L-NAME pretreatment (VE/L-NAME). In these rats, con-
comitant treatment with DPCPX (VD/L-NAME/DPCPX)
was equally effective in preventing RCIN as was VE alone.
Values are shown in Table 1.
RCIN can be defined as a form of acute renal functional
deterioration following intravascular administration of io-
dinated RCM. The pathogenesis of RCIN is incompletely
understood. In general, RCM elicit distinct effects on renal
hemodynamics and on tubular function [7]. RCM induce
intrarenal hypoxia, related to renal vasoconstriction and/or
osmotic stress [7]. Increased intrarenal adenosine levels, as
a result of enhanced ATP-hydrolysis, may be a major factor
in the development of acute renal failure following RCM
administration. This assumption is supported by the in-
creased urinary adenosine excretion following RCM [8]
and by the successful prevention of RCM-induced nephro-
toxicity by adenosine receptor antagonists [2, 3]. Factors
enhancing adenosine-induced renal vasoconstriction, such
as ECV contraction by hemorrhage or low-NaCl diet [9] or
inhibition of cyclooxygenase or NO-synthase [6, 10], aggra-
vate RCIN-induced nephropathy. Conversely, factors re-
ducing adenosine-induced vasoconstriction in the kidney
attenuate RCIN. This study, using the new L-NAME-
hypertensive, chronic NO-depleted rat model, provides
additional evidence for the importance of adenosine in the
etiology of RCM-induced acute renal failure. In this model,
administration of the specific antagonist DPCPX is equally
effective as ECV expansion induced by high NaCl intake in
preventing RCM-induced renal impairment.
Extrapolation these findings to clinical settings implies
administration of adenosine antagonists to prevent renal
impairment following RCM administration in patients with
pre-existing risk factors (diuretics, cyclooxygenase inhibi-
tors, volume contraction, high plasma renin activity) and in
patients in whom volume expansion is contraindicated.
APPENDIX
Abbreviations used in this article are: ATP, adenosine triphosphate; BP,
blood pressure; DPCPX, 8-cyclopropyl-1,3-dipropylxanthine; ECV, extra-
cellular volume; GFR, glomerular filtration rate; L-NAME, nitro-L-Arg
methyl ester; MAP, mean arterial pressure; NO, nitric oxide; RBF, renal
blood flow; RCIN, radiocontrast media-induced nephropathy; RCM,
radiocontrast medium; VD, volume depleted; VE, volume expanded.
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